Known targets — ChEMBL curated mechanism
ADRB1ADRB2SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Propafenone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 1.00 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 17/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | KCNK3 | O14649 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCC9 | O60706 | 1/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propafenone SCHEMBL30416841 | 1.00 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL16730120 | 1.00 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL41413 | 1.00 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL29384899 | 0.99 | MEN1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL41412 | 0.99 | MEN1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL5529275 | 0.99 | MEN1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL1651012 | 0.98 | ABCB1 (0.96) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| SCHEMBL29419081 | 0.94 | ABCB1 (0.88) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL15539494 | 0.91 | ABCB1 (0.83) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL924632 | 0.89 | ABCB1 (0.79) | ABCB1LMNACYP1A2CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13701 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260061000-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS, INCLUDING ATRIAL FIBRILLATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2026-03-05 | — | — | US | claimed |
| US-12534571-B2 | Amphiphilic block copolymer, preparation method thereof and nanomicelle drug-loading system | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2026-01-27 | — | — | US | claimed |
| US-20260007719-A1 | COMPOSITION FOR INTERMITTENT DOSING OF CALCINEURIN INHIBITORS | KLEE TREVOR (US) | 2026-01-08 | — | — | US | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| US-20250360149-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS INC (KR) | 2025-11-27 | — | — | US | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| WO-2025050091-A9 | THERAPEUTIC PEPTIDES TO MANAGE ATRIAL FIBRILLATION | OHIO STATE INNOVATION FOUNDATION (US) | 2025-06-19 | — | — | WO | claimed |
| EP-0642799-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | claimed |
| EP-0484331-B1 | MONOCRYSTALS OF $g(b)-PHENYLPROPIOPHENONES | KNOLL AG (DE) | 1994-01-19 | — | — | EP | claimed |
| EP-0406327-B1 | LONG LASTING COMPOSITION OF PROPAFENONE AND QUINIDINE FOR TREATMENT OF CARDIAC CONDITIONS | KNOLL PHARMACEUTICAL COMPANY (US) | 1993-08-11 | — | — | EP | claimed |
| US-5230901-A | Gallopamil or propafenone | KNOLL AG (DE) | 1993-07-27 | — | — | US | claimed |
| EP-0406327-A1 | LONG LASTING COMPOSITION OF PROPAFENONE AND QUINIDINE FOR TREATMENT OF CARDIAC CONDITIONS. | BASF K & F CORP (US) | 1991-01-09 | — | — | EP | claimed |
| US-4954347-A | Long lasting composition of propafenone and quinidine for treatment of cardiac conditions | BASF K & F CORP. (US) | 1990-09-04 | — | — | US | claimed |
| WO-1989010743-A1 | LONG LASTING COMPOSITION OF PROPAFENONE AND QUINIDINE FOR TREATMENT OF CARDIAC CONDITIONS | BASF K & F CORP. (US) | 1989-11-16 | — | — | WO | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| CN-85102275-A | NEW PROCESS FOR SYNTHESIZING PROPAFENONE | — | 1985-11-10 | — | — | CN | claimed |
| US-4474986-A | Preparation of propafenone | BASF AKTIENGESELLSCHAFT (DE) | 1984-10-02 | — | — | US | claimed |